TG THERAPEUTICS, INC.
Close on Oct 19, 2026
- Market cap
- $8.38B
- P/E (TTM)
- 19.5
- Dividend yield
- –
About Tg Therapeutics
Pharmaceutical Preparations, SIC 2834
TG Therapeutics is a commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing targeted therapies for B-cell mediated conditions, primarily focusing on multiple sclerosis. Its lead commercial product is BRIUMVI (ublituximab-xiiy), an intravenously infused anti-CD20 monoclonal antibody approved to treat adult patients with relapsing forms of multiple sclerosis. The company also advances investigational candidates in its clinical pipeline, including a subcutaneous formulation of ublituximab and an allogeneic CAR T cell therapy known as azer-cel, while providing its therapeutic treatments directly to healthcare professionals and patients.
The business operates internationally, distributing BRIUMVI across the United States as well as within Europe, where it initially entered the market in Germany through an ex-U.S. commercialization partnership and expanded to several other countries. TG Therapeutics maintains corporate executive offices located in Morrisville, North Carolina.
Summary of the business section of Tg Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- TG THERAPEUTICS, INC.
- Founded
- 1993
- Headquarters
- New York, NY
- Address
- 2 Gansevoort Street, 9th Floor 10014
- Phone
- (212) 554-4484
- Website
- tgtherapeutics.com
- Employees
- 399, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, New York, NY
Stock & identifiers
- Ticker
- TGTX
- Exchange
- Nasdaq
- IPO date
- May 3, 2010
- Shares outstanding
- 153M, Aug 3, 2026
- Public float
- $2.50B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 1-for-50 reverse, Jul 14, 2011
- SEC CIK
- 1001316
- CUSIP
- 88322Q108
- ISIN
- US88322Q1085
- LEI
- 529900X21UKABN9NJ529
- EIN
- 36-3898269
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Michael S. Weiss | CEO, Director | 22,846,168 |
| Sean A. Power | CFO | 798,111 |
| Laurence N. Charney | Director | 168,640 |
| Sagar Lonial | Director | 94,061 |
| Yann Echelard | Director | 223,816 |
| Kenneth Hoberman | Director | 279,653 |
| Daniel Hume | Director | 192,748 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr. Weiss | $25.57M | $28.30M | $3.77M | $57 | $120 |
| FY2024 Mr. Weiss | $18.75M | $91.74M | $2.25M | $58 | $91 |
| FY2023 Mr. Weiss | $18.47M | $41.18M | $1.87M | $33 | $92 |
| FY2022 Mr. Weiss | $10.44M | -$42.94M | $1.97M | $23 | $89 |
| FY2021 Mr. Weiss | $42.67M | -$114.07M | $1.51M | $37 | $99 |
| FY2020 | $32.50M | $191.43M | $7.12M | $469 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of February 20, 2026, we had 399 employees.”
Corporate history
Events identified from SEC filings